Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission.
Preclinical data have shown that addition of the selective norepinephrine transporter (NET) inhibitor reboxetine increases the antipsychotic-like effect of the D(2/3) antagonist raclopride and, in parallel, enhances cortical dopamine output. Subsequent clinical results suggested that adding reboxetine to stable treatments with various antipsychotic drugs (APDs) may improve positive, negative and depressive symptoms in schizophrenia. In this study, we investigated in rats the effects of adding reboxetine to the second-generation APD olanzapine on: (i) antipsychotic efficacy, using the conditioned avoidance response (CAR) test, (ii) extrapyramidal side effect (EPS) liability, using a catalepsy test, (iii) dopamine efflux in the medial prefrontal cortex and the nucleus accumbens, using in vivo microdialysis in freely moving animals and (iv) cortical N-methyl-D-aspartate (NMDA) receptor-mediated transmission, using intracellular electrophysiological recording in vitro. Reboxetine (6 mg/kg) enhanced the suppression of CAR induced by a suboptimal dose (1.25 mg/kg), but not an optimal (2.5 mg/kg) dose of olanzapine without any concomitant catalepsy. Addition of reboxetine to the low dose of olanzapine also markedly increased cortical dopamine outflow and facilitated prefrontal NMDA receptor-mediated transmission. Our data suggest that adjunctive treatment with a NET inhibitor may enhance the therapeutic effect of low-dose olanzapine in schizophrenia without increasing EPS liability and add an antidepressant action, thus in principle allowing for a dose reduction of olanzapine with a concomitant reduction of dose-related side effects, such as EPS and weight gain.
Marcus
Monica M
MM
Section of Neuropsychopharmacology, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Jardemark
Kent
K
Malmerfelt
Anna
A
Björkholm
Carl
C
Svensson
Torgny H
TH
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001362:Avoidance Learning / Q000187:drug effects*; D001522:Behavior, Animal / Q000187:drug effects; D001569:Benzodiazepines / Q000494:pharmacology*; D002540:Cerebral Cortex / Q000187:drug effects* / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D046352:Freezing Reaction, Cataleptic / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D017551:Microdialysis / Q000379:methods; D009025:Morpholines / Q000494:pharmacology*; D016202:N-Methylaspartate / Q000494:pharmacology; D000077152:Olanzapine; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D000077593:Reboxetine; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*
D014150:Antipsychotic Agents; D018690:Excitatory Amino Acid Agonists; D009025:Morpholines; D016194:Receptors, N-Methyl-D-Aspartate; D001569:Benzodiazepines; D016202:N-Methylaspartate; D000077593:Reboxetine; D000077152:Olanzapine; D004298:Dopamine
Ther Drug Monit. 2001 Feb;23(1):27-34
11206039
Br J Psychiatry Suppl. 1996 May;(29):17-22
8733819
Isr J Psychiatry Relat Sci. 2009;46(3):213-20
20039523
Synapse. 2006 Aug;60(2):102-8
16715496
Neuroscience. 2006 Feb;137(3):1039-49
16298081
Int J Neuropsychopharmacol. 2007 Apr;10(2):191-202
16707032
Arch Gen Psychiatry. 2003 Jan;60(1):82-91
12511175
Eur Psychiatry. 2004 Sep;19(6):366-9
15363476
J Clin Psychiatry. 2000;61 Suppl 11:9-17
10926050
Mol Psychiatry. 2001 Nov;6(6):657-64
11673793
J Clin Psychopharmacol. 2008 Feb;28(1):59-63
18204342
J Psychopharmacol. 2009 Jan;23(1):65-73
18308814
Science. 1999 Oct 1;286(5437):105-7
10506554
J Neurochem. 1990 Sep;55(3):1067-70
2117046
Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73
8935801
Psychopharmacology (Berl). 2008 Feb;196(3):417-29
17940749
Pharmacol Biochem Behav. 1986 May;24(5):1409-15
2873588
J Neurophysiol. 1985 Oct;54(4):782-806
2999347
Curr Neuropharmacol. 2006 Apr;4(2):115-25
18615131
Arch Gen Psychiatry. 1988 Jan;45(1):71-6
2892477
Neuropsychopharmacology. 2006 Sep;31(9):1991-2001
16738543
Science. 2006 Feb 10;311(5762):861-3
16469930
Psychopharmacology (Berl). 1998 Mar;136(2):153-61
9551772
Biol Psychiatry. 2005 Aug 15;58(4):337-43
16102547
J Pharmacol Toxicol Methods. 1994 Nov;32(3):155-9
7858309
Int J Neuropsychopharmacol. 2010 Aug;13(7):891-903
19835668
J Neurosci. 2002 May 1;22(9):3708-19
11978847
Lancet. 2009 Jan 3;373(9657):31-41
19058842
Psychopharmacology (Berl). 2000 Jul;150(4):422-9
10958084
Arch Gen Psychiatry. 2003 Jun;60(6):553-64
12796218
Schizophr Bull. 2006 Oct;32(4):715-23
16540702
J Psychopharmacol. 1997;11(4 Suppl):S9-15
9438228
Ann N Y Acad Sci. 2003 Nov;1003:318-27
14684455
J Clin Psychiatry. 2009 Apr;70(4):526-39
19358790
Am J Psychiatry. 2006 Apr;163(4):600-10
16585434
Acta Pharmacol Toxicol (Copenh). 1982 Oct;51(4):321-9
6129770
Psychopharmacology (Berl). 2007 Jun;192(3):441-8
17310385
Prog Neurobiol. 2007 Oct;83(2):69-91
17681661
Int J Neuropsychopharmacol. 2010 Apr;13(3):305-20
19691907
J Psychopharmacol. 2007 Jun;21(4):440-52
17259207
Trends Neurosci. 1990 Mar;13(3):99-104
1691879
Schizophr Res. 2006 Jul;85(1-3):222-31
16679001
J Clin Psychiatry. 2009 Apr;70(4):540-9
19358791
Neuroscientist. 2003 Oct;9(5):404-16
14580124
Psychopharmacology (Berl). 2004 Feb;171(4):365-74
14668973
Schizophr Res. 2005 Mar 1;73(2-3):139-45
15653256
J Neurochem. 1994 Jul;63(1):195-200
8207428
Am J Psychiatry. 2000 Apr;157(4):514-20
10739409
Int J Neuropsychopharmacol. 2005 Sep;8(3):315-27
15857571
Psychopharmacology (Berl). 1999 Jan;141(2):175-81
9952042
J Neurophysiol. 2002 May;87(5):2324-36
11976371
Int Clin Psychopharmacol. 1999 May;14 Suppl 1:S27-31
10468326
Neuropsychopharmacology. 2002 Nov;27(5):691-8
12431844
Psychopharmacology (Berl). 1994 Jun;115(1-2):147-56
7862887
Prog Brain Res. 2008;172:177-97
18772033
Eur J Neurosci. 2003 Mar;17(6):1306-12
12670320
Int Clin Psychopharmacol. 2003 Jan;18(1):9-14
12490769
J Neurochem. 1990 May;54(5):1755-60
1969939
Neuropsychopharmacology. 2008 Aug;33(9):2175-86
18033238
J Pharmacol Exp Ther. 1997 Oct;283(1):226-34
9336328
Behav Neural Biol. 1989 May;51(3):401-11
2543356
Neurosci Biobehav Rev. 1999;23(6):851-62
10541060
Psychiatr Serv. 2008 May;59(5):500-6
18451005
Eur J Pharmacol. 1998 Nov 13;361(1):27-33
9851538
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1145-58
14642973
Synapse. 2003 May;48(2):66-79
12619040
J Psychopharmacol. 2000;14(4):409-18
11198061
Psychopharmacology (Berl). 2004 Jun;174(1):3-16
15118803
Am J Psychiatry. 2003 Feb;160(2):297-302
12562576
Clin Pharmacokinet. 2000 Dec;39(6):413-27
11192474
Int Clin Psychopharmacol. 2001 Sep;16(5):275-8
11552770
Neuropsychopharmacology. 2001 Nov;25(5):633-41
11682246
Arch Gen Psychiatry. 1988 Sep;45(9):789-96
3046553
Can J Psychiatry. 2005 Jul;50(8):462-9
16127964
Am J Psychiatry. 1995 Oct;152(10):1444-9
7573582